Clinical and basic evidence suggests that both large artery and small vessel disease contribute to the pathogenesis of Alzheimer disease, one form of dementia. Although the study of the cause of Alzheimer disease began with a vascular emphasis, the field shifted to a focus on neuronal changes in response to local amyloid β peptides (Aβ), subsequent Tau pathology, and their ultimate effects on cognitive function. In more recent years, a partial realignment has occurred, such that vascular disease is again thought to make important contributions to Alzheimer disease pathology (along with other dementias) and their impact on brain function.

The term neurovascular unit (NVU) is commonly used to emphasize the concept that in brain, vascular cells (endothelium, vascular muscle, and pericytes) are closely associated anatomically and functionally with perivascular cells (eg, astrocytes, neurons, and microglia). In the literature, the cellular makeup of the NVU varies. For example, some presentations include vascular muscle, but others do not, despite the fact that vascular muscle is the major effector of rapid changes in lumen diameter in resistance vessels. Reasons for differences in definition are not clear but may include the fact that cellular components of the NVUs vary with progression along the vascular tree (Figure). Within individual segments of the vasculature, further heterogeneity exists. For instance, astrocytic endfeet associates to a fairly high degree with vascular muscle in the striatum but not in the cortex. When the discussion relates to the blood–brain barrier, the focus is typically capillary centric, and vascular muscle is often omitted.

Perivascular macrophages (PVM) are an additional cell within the NVU. This cell type is distinct from peripheral macrophages and the various resident microglia in brain. PVM are found in close proximity to pial arterioles and the more proximal arterioles within the parenchyma but not more distal arterioles and capillaries (Figure). Although the presence of PVM within the microcirculation has been known for many years, the functional importance of these cells under normal conditions and in disease is poorly defined.

Previous work implicated oxidative stress and reactive oxygen species (ROS) in effects of Aβ on isolated blood vessels along with regulation of vascular tone and cerebral blood flow (CBF) in vivo. Both vascular and nonvascular cells are capable of producing ROS. Thus, multiple cells within or near the vasculature are candidate sources of ROS and sites of oxidative stress in Alzheimer disease. Within vascular cells, a major enzymatic source of ROS is the family of NADPH oxidases.

In this issue of Circulation Research, Park et al examined the hypothesis that a Nox2 containing NADPH oxidase within PVM is the main source of superoxide that impairs regulation of CBF in models of Aβ-induced pathophysiology. To pursue this question, complementary approaches were used that included alterations in local levels of Aβ and pharmacological and genetic manipulation of PVM numbers and genotype, focusing on the role of Nox2 and CD36, a receptor that activates NADPH oxidase in the PVM. The study relied on 2 models, one that examined acute effects of Aβ and the second, a genetic model that chronically expresses a Swedish mutation in amyloid precursor protein. Using these models, the impact of Aβ on several key vasodilator mechanisms was quantified. Both acute and chronic exposure to elevated levels of Aβ increased ROS and impaired local CBF responses to endothelium-dependent agonists (both NO-dependent and NO-independent), to an NO donor, and to activation of the somatosensory cortex, a model of neurovascular coupling. In contrast, changes in CBF during hypercapnia and local application of adenosine (a vasodilator that acts directly on vascular muscle) were not altered by Aβ.

The authors next addressed potential mechanisms involved. Oxidative stress contributes to vascular abnormalities in many disease models including Alzheimer disease. Depletion of PVM using centrally administered clonodronate inhibited increases in ROS and CBF abnormalities in both the acute and chronic models of Aβ-induced dysfunction. In further studies, the use of bone marrow transfer and genetically altered mice suggested the cell type expressing CD36 and Nox2, and mediating effects of Aβ on regulation of CBF, was the PVM. This conclusion was based on several observations, including the fact that genetic deletion of Nox2 within the PVM prevents effects of Aβ on local levels of ROS and CBF. Findings such as this elevate the PVM from a cellular bystander with unknown intentions to a functionally important contributor to cerebrovascular abnormalities in models of Alzheimer disease. The concept that PVM in brain contribute to cerebrovascular disease is also reinforced by recent work in models of hypertension.
Although the study by Park et al provides new insight into PVM-dependent mechanisms in brain, new questions emerge, and some questions were left unanswered. First, only male mice were used in the study. Because Alzheimer disease is more common in women than in men, it will be important to also define the role of central PVM in female preclinical models. Second, the product of Nox2 is superoxide, a precursor to other ROS and related molecules (Figure). Such interactive chemistry raises the question, was the phenotype because of effects of superoxide per se, some downstream molecule, or the collective impact and interaction of several molecules? How does superoxide produced by a PVM affect the distinct cells and regulatory mechanisms that mediate endothelium-dependent vasodilation and neurovascular coupling? Third, although the current study implicates PVM as a key source of superoxide, this cell type is likely not the only producer of superoxide or location of oxidative stress within the vasculature. For example, other work using a similar model of Alzheimer disease highlighted endothelial cells as a key site of increased superoxide. Thus, although details remain to be defined, it seems likely that multicellular and possibly integrated sites of oxidative stress are involved in changes during Alzheimer disease. Fourth, only acute or early vascular effects of Aβ were studied. The potential impact of PVM-mediated changes in regulation of CBF on cognitive or noncognitive function in brain remains to be determined. Fifth, integrity of the blood–brain barrier can be lost during Alzheimer disease. The blood–brain barrier is present throughout the various segments of the vasculature in the brain (Figure). Is there a role for PVM in changes in blood–brain barrier structure and function as well? Finally, can targeting of PVM in mice after Aβ-dependent disease is established reverse vascular abnormalities and cognitive deficits?

What are the implications of this work? With essentially no energy reserves, adequate resting CBF and effective regulatory mechanisms are needed on a moment-to-moment basis to ensure precise delivery of oxygen, glucose, and other molecules required for normal brain function. Accumulating evidence suggests that hypoperfusion resulting from abnormalities in this regulation are a prelude and a predictor of dementia. The structural and functional changes that produce such reductions in CBF and their underlying mechanisms remain to be fully defined. Manipulation of PVM, a component of the NVU in some segments of the circulation, was sufficient to prevent the impairment of 2 key adaptive vasodilator mechanisms in models of Alzheimer disease. With such work, the shift in concept that disruption in vascular mechanisms plays a major role in the pathophysiology of brain dysfunction and dementias gains further momentum, while highlighting a possible direct role for PVM in small vessel disease.

**Sources of Funding**

This work was supported by the National Institutes of Health (HL-113863 and NS-096465), the Department of Veterans Affairs (BX001399), and the Fondation Leducq (Transatlantic Network of Excellence).

**Disclosures**

None.

**References**


Disease Highlights the Cellular Diversity of Neurovascular Units: Sign in Stranger
Frank M. Faraci

Circ Res. 2017;121:203-205
doi: 10.1161/CIRCRESAHA.117.311386

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/121/3/203

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/